Toggle light / dark theme

A newly developed stretchable lithium-ion battery retains efficient charge storage after 70 cycles and expands up to 5000%. This innovation caters to the growing demand for batteries in wearable electronics, ensuring flexibility and durability.

When you think of a battery, you probably don’t think of something stretchy. However, batteries will need this shape-shifting quality to be incorporated into flexible electronics, which are gaining traction for wearable health monitors. Now, researchers in ACS Energy Letters report a lithium-ion battery with entirely stretchable components, including an electrolyte layer that can expand by 5000%, and it retains its charge storage capacity after nearly 70 charge/discharge cycles.

Advancements in Flexible Electronics.

In the age of technology everywhere, we are all too familiar with the inconvenience of a dead battery. But for those relying on a wearable health care device to monitor glucose, reduce tremors, or even track heart function, taking time to recharge can pose a big risk.

For the first time, researchers in Carnegie Mellon University’s Department of Mechanical Engineering have shown that a health care device can be powered using alone. By combining a pulse oximetry sensor with a flexible, stretchable, wearable thermoelectric energy generator composed of , semiconductors, and 3D printed rubber, the team has introduced a promising way to address battery life concerns.

“This is the first step towards battery-free wearable electronics,” said Mason Zadan, Ph.D. candidate and first author of the research published in Advanced Functional Materials.

As space travel becomes more common, it is important to consider the impacts of space flight and altered gravity on the human body. Led by Dr. Ana Diaz Artiles, researchers at Texas A&M University are studying some of those impacts, specifically effects on the eye.

Gravitational changes experienced by astronauts during space travel can cause fluids within the body to shift. This can cause changes to the cardiovascular system, including vessels in and around the eyes.

As the commercialization of space flight becomes more common and individual space travel increases, astronauts will not be the only ones experiencing these changes. Individuals traveling to space with commercial companies may not be as fit or healthy as astronauts, making it even more important to understand the role that fluid shift plays in cardiovascular and eye health.

Furthermore, the synergy between educational programs, cultural influences and the tangible benefits derived from space exploration not only enriches our present-day society but also ensures a legacy of continuous innovation and exploration. This ongoing engagement with space inspires future generations to look beyond our planetary boundaries and consider what might be possible in the broader cosmos.

Space exploration presents significant challenges, including costs, astronaut health risks and technological hurdles for interstellar travel. Ethical and legal considerations regarding space colonization, resource utilization and celestial environmental impact require careful consideration and international cooperation.

While Silicon Valley visionaries envision a future among the stars, other voices remind us of our responsibilities to Earth. These are not mutually exclusive goals. By leveraging advancements and opportunities from space exploration, we can better protect and enhance life on Earth. Through economic benefits, scientific advancement and social inspiration, space exploration remains a crucial endeavor for humanity, not as an escape from our problems, but as a way to expand our horizons and solve them on our home planet.

The Maximum Absorbency Garment (MAG)—that collects urine and feces during extravehicular activities (EVAs) that last up to 8 h. Such exposure to waste for prolonged periods of time contributes to hygiene-related medical events, including urinary tract infections and gastrointestinal distress. Historically, prior to using the MAG, astronauts have limited their food intake or eaten a low-residue diet before embarking on physically demanding spacewalks, reducing their work performance index (WPI) and posing a health risk. Furthermore, the current 0.95 L In-suit Drink Bag (IDB) does not provide sufficient water for more frequent, longer-range spacewalks, which carry greater potential for contingency scenarios requiring extended time away from a vehicle.

NASA has invested $725,000 in a new rocket system that could solve one of the major obstacles standing in our way of sending humans to Mars: travel time.

With current technology, a round-trip to the red planet would take almost two years. For astronauts, spending that much time in spaceflight comes with big health risks.

They’d be exposed to high levels of solar and cosmic radiation, the harmful effects of zero-gravity, and a long period of isolation.

This study presents a discovery in the fight against hepatocellular carcinoma (HCC) by identifying the protein Schlafen 11 (SLFN11) as a key factor influencing the effectiveness of immune checkpoint inhibitors (ICIs). Through comprehensive analysis using humanized orthotopic HCC mouse models and in vitro co-culture systems, the research unveils how SLFN11’s deficiency in tumor cells leads to an increase in C-C motif chemokine ligand 2 (CCL2) secretion. This phenomenon promotes the infiltration of immunosuppressive macrophages and leads to immune evasion. The study also showcases the therapeutic potential of blocking CCL2/CCR2 signaling to enhance the efficacy of ICIs in patients with low SLFN11 expression. These findings pave the way for future research to explore additional therapeutic targets within the immune landscape of HCC, offering hope for more effective treatments and improved patient outcomes.

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with advanced stages showing dismal survival rates due to limited treatment efficacy. The efforts to improve the situation have focused on immunotherapies, such as immune checkpoint inhibitors (ICIs), though their success varies significantly among individuals due to the complex interplay of tumor growth and immune evasion within the tumor microenvironment (TME). Previous studies have hinted at the role of tumor-associated macrophages (TAMs) and chemokines like CCL2 in the functional remodeling of TAMs. However, a comprehensive understanding of the mechanisms driving immune evasion and therapy resistance in HCC has been lacking. This research proposes a solution by identifying SLFN11’s role in modulating the immune landscape of HCC, specifically its influence on macrophage polarization and CCL2 signaling. The outcome offers new avenues for enhancing ICI therapy effectiveness.

Statistics from the World Health Organization reveal that liver cancer, primarily hepatocellular carcinoma (HCC), contributes significantly to the cancer mortality rate. This research highlights the urgency of developing more effective treatments for HCC, aligning with SDG 3 (Good Health and Well-being) by aiming to reduce premature mortality from cancer and promote access to quality essential healthcare services. Moreover, by elucidating novel targets for therapeutic intervention, this study contributes to SDG 9 (Industry, Innovation, and Infrastructure), fostering innovation through the development of new and effective treatments for HCC.

Up to 3% of people with diabetes have an allergic reaction to insulin. A team at Forschungszentrum Jülich has now studied a method that could be used to deliver the active substance into the body in a masked form—in the form of tiny nanoparticles.

The insulin is only released in the target organ when the pH value deviates from the slightly alkaline environment in the blood. The molecular transport system could also serve as a platform for releasing other drugs in the body precisely at the target site.

It’s an old dream in pharmacy: To deliver an active ingredient to the exact place in the body where it is most needed—a cancer drug, for example, directly to the tumor tissue. This minimizes its side effects on other organs and ensures that it has its maximum effect at its target.

Over the recent decades, comprehensive genome-wide association studies (GWAS) have indicated the potential influence of genetic factors on one’s alcohol consumption volume and identified over 100 related variants6,7. However, a predominant proportion of the identified variants are localized within noncoding regions, and their effect sizes tend to be small, making interpretation and identification of the causal gene challenging8. In addition, previous GWAS mainly utilized imputed genotype data, which only cover limited regions of the genome, and thus may have missed many potential genes. Furthermore, GWAS studies focused mainly on common variants, and few studies have investigated rare variants associated with alcohol consumption, which yield greater potential to interpret biological function and elucidate mechanisms9. Although there are studies that have attempted to leverage exome chip data to identify rare variants contributing to alcohol consumption, the sample size was small and limited regions of the whole exome were examined10.

The introduction of whole exome sequencing (WES) provides a great chance to overcome the limitations of previous genetic studies on alcohol consumption with a substantially larger amount of rare and ultra-rare protein-coding variants11,12,13. Collapsing of loss-of-function (LOF) variants helps estimate the effect direction of associated genes13,14. When combined with large-scale population cohorts with multi-modal phenotypic data, WES would greatly facilitate our understanding of the genetic underpinnings of alcohol consumption as well as its implication on physical and mental health6. However, to our knowledge, there have been few large-scale WES studies on alcohol consumption, let alone elucidating the potential implications of the identified genes10,15. Meanwhile, as indicated by a previous genome-wide association study, significant genetic associations existed between alcohol consumption and several body health phenotypes7. The application of phenome-wide analysis for alcohol-related genes can help extend and deepen our current comprehension of the association between alcohol consumption and human health.

Hence, aiming to refine the genetic architecture of alcohol consumption, we conduct an exome-wide association study (ExWAS) for alcohol consumption among 304,119 individuals from the UK Biobank (UKB). We also examine the rare-variant associations with genes reported by previous GWAS6,7,16,17. Finally, we provide biological insights into the identified genes via bioinformatics analyses and phenome-wide association analysis (PheWAS).